Materials and Methods
The Bio-miRTa Algorithm Input data: Initially, Bio-miRTa requires the miRNA ID (or IDs) and the species (human or mouse). Subsequently gene sets from functional perturbations, such as miRNA gain-of-function and loss-of-function studies, as well as from descriptive data, such as gene expression in different stages of cancer progression or other biological conditions being compared, is incorporated for the ranking of candidate gene targets in the second step.
Step 1: miRNA target extraction:
To identify potential targets of miRNAs, Bio-miRTa uses four different target prediction algorithms: Computational target prediction algorithms predict numerous potential target genes for each miRNA, with a propensity of high number of false positives (1, 2) . Therefore, to reduce the number of false positive targets, apart from including four different datasets, we also included two additional datasets of experimentally validated miRNA targets to the Bio-miRTa pipeline: 5. TarBase (diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index) 6 . starBase (starbase.sysu.edu.cn/). For each miRNA, Bio-miRTa extracts the predicted target genes in all six databases, and then, for each gene, a Prediction Score (PS) is defined as following:
Where & is the prediction score of dataset i (= 0.15 for prediction algorithms and 0.2 for experimentally validated datasets), and . #& is equal to 1 if and only if gene x is presented in dataset i, otherwise it is equal to 0. The maximum achievable # is equal to 1.
As a result, a gene is considered as the potential target of the miRNA if # ≥ 0.3, i.e., it is predicted to have an MRE by at least two target prediction algorithms, or one prediction algorithm and one experimentally verified database ( Fig. 4) .
Additionally, Bio-miRTa extracts the number of predicted MREs for the queried miRNA within 3'-UTR of the predicted target genes. This information is extracted for each target prediction algorithm separately, and reported in the final table.
In the cases where multiple related miRNAs with highly-similar or identical seed sequences are studied, such as miRNA clusters, Bio-miRTa runs the first step for each miRNA separately, and then takes the union of all target genes as the list of potential targets for the miRNA cluster.
The final PS for a gene x is computed as follows:
where # & is # for miRNA i, and n is the total number of miRNAs in the cluster (Fig. S4) .
At the end of the first step, Bio-miRTa provides a list of potential target genes for the miRNA(s) of interest, which are ranked according to the PS.
Step 2: Experimetal dataset incorporation and final ranking of the candidate target genes.
In the second step Bio-miRTa has the ability to incorporate multiple datasets that are assigned with a Biological Score (BS) according to their inferred biological relevance. Eventually
Bio-miRTa calculates the final BS for each gene as the following:
Where & is the biological score of dataset i (defined by the user), n is the number of datasets provided by the user, and . #& is equal to 1 if and only if gene x is presented in dataset i, otherwise it is equal to 0.
As a default, Bio-miRTa assigns a BS of 1 to the submitted datasets in the second step.
Therefore, the BS of a given dataset would always be equal or greater than the PS. In additon, in the case of multiple datasets, Bio-miRTa allows the user to assign different BS to each dataset according ot their perceived importance and biological relevance. This is illustrated in the section below describing the application of Bio-miRTa in this study and in the Results of the main text.
Finally, the list of potential target genes is further ranked by assigning a Final Score (FS) to each gene, which is the sum of two independent scores: the Prediction Score (PS) and the Biological Score (BS).
Additionally, Bio-miRTa allows the converse analysis, in which a potentially miR-regulated gene is known, and the question to be addressed is whether there are high scoring miRNAs that target MREs in that gene, identified in a reverse step 1, and also score in a reverse step 2, where biologically relevant miRNA expression datasets are incorporated.
Application of Bio-miRTA for the identification of miR-137 and miR-23b cluster biologically relevant gene targets, and Inhßb regulatory miRNAs.
We ran Bio-miRTa on miR-137 and the miR-23b cluster, which is composed of miR-23b, miR-27b, and miR-24-1. The analysis was performed considering the mouse as the selected species for target prediction. We also provided Bio-miRTa with the following three datasets of biologically relevant information:
1. The set of significantly down-regulated genes (more than 1.2-fold) upon over-expression of the miRNA in ßTC3 cell line (BS = 2).
2. The set of significantly down-regulated genes (more than 1.5-fold) in MLP versus IT tumor samples dissected from human patients (BS = 1).
3. The set of significantly down-regulated genes (more than 1.5-fold) in MLP versus IT tumor samples dissected from RipTag2 model (BS = 1).
The rational for the different weighting scores is explained in the Results section. The final lists for the miR-137 and the miR-23b cluster's biologically relevant target genes are shown in Datasets S2 and S3, respectively.
To assess the potential miRNAs targeting Activin-B (Inhßb), we ran Bio-miRTa in reverse
for Inhßb, considering the mouse as the selected species. Thus, for step 1, we queried each of the six algorithms to identify miRNAs that define MREs within the 3' UTR for Inhßb, differentially assigning scores as described above to a maximum value of 1.0, if all six were concordant. To calculate the BS, we used a single set of significantly up-regulated miRNAs (more than 1.5-fold) in PanNETs compared to normal pancreatic islet cells (3) . The BS for this miRNA dataset was therefore defined as BS=1. The complete list of miRNAs implicated as modulators of Inhßb is shown in Dataset S4, while the top scoring miRNAs are shown in Figure S5 .
Animal Studies
SCID/beige mice (from Taconic) were maintained in a pathogen-free barrier animal facility according to the Swiss regulations, and male, 8-10 weeks old, mice were used for all studies.
For orthotopic tumor models, fifty thousand ßTC3 cells in 50 µl of sterile PBS were injected in the parenchyma of the pancreas in a region proximal to the spleen.
As we have previously published (4), neuroendocrine cancer cells preferentially metastasize to the liver following tail vein injections; thus, to model the late stages of liver metastasis, we mainly used this route of inoculation instead of injections into the portal vein or spleen. One hundred thousand cells for both the ßTC3 and STC-1 in 200 µl of sterile PBS were injected into a lateral tail vein. To model the early stages of liver metastasis, we used intra spleen injections to deliver the cells via the portal vein circulation to the liver. One hundred thousand cells in 100 µl of sterile PBS were injected into the exteriorized spleen. The spleen was removed four minutes after injection to allow enough time for the cells to enter the circulation.
EdU Cell Proliferation Assays
The proliferation of cancer cells in-vivo was performed as we have previously described (4) . Briefly, mice were injected intraperitoneally with 100 µg of EdU in PBS. One hour post-injection, they were anesthetized using pentobarbital sodium and transcardially perfused with 20 ml of PBS, followed with 20 ml of 1% PFA.
Mouse mRNA Sequencing
The RNA quality of the samples was assessed using the Fragment Analyzer (Advanced Analytical Technologies, Inc., Ankeny, IA, USA), and all samples had RQN > 9.0. We used 500 ng of total (6).
DNA synthesis
The following fragments were synthesized using GeneArt Gene Synthesis service from Thermofisher:
A. SORL1-3'UTR Fragment: GRCh38/hg38 chr11:121,633,282-121,633,762; 481 bp. The MRE-mutant was also synthesized according to the sequence shown in Figure S4 . XbaI and BsaBI), and the PCR products of the primer pairs listed in the supplementary table S1 were used for assembly. The resulting pENTR vectors were used for subcloning into the pcDHA-effLuc-RfA destination vector.
Knockdown experiments
For the generation of gene knockdown, we generated vectors coding for tandem miR-E based shRNAs as we have previously described (4).
piggyBac vectors
PiggyBac transposon vectors used in this study have been previously described (4) .
Transfections
One million cells were plated in 6-well plates 24 hrs before transfection. The following day the media was changed 2 hrs before transfections. 
Cell culture treatment with recombinant proteins (cytokines) and antagomirs
Upon arrival, activin B (R&D Systems; Cat# 8260-AB-010) was resuspended according to the manufacturer's instructions, aliquoted and stored at -20 o C. Care was taken not to thaw the aliquots more than one time.
One million cells were plated in 6-well plates 24 hrs before addition of recombinant proteins. The following day, the media was changed, and the appropriate amount of recombinant protein was added.
Invasion assays
Invasion assays were performed as previously described (7). ßTC3 control or miR-23b cluster overexpressing cells were used in DOX containing media.
Reporter assays
The vector destination vector pcDHA-effLuc-RfA was made for assessing the activity of MREs in The complexes were incubated for 20-30 min at room temperature and then applied dropwise to the cells. After 24 hrs of adding the complexes, the media was changed to fresh DOX media. Forty-eight hours after the luciferase and ß-galactosidase activity was measured according to the manufacturer's instructions. Briefly, the 24-well plates were washed with cold PBS and 120 µl of CCLR lysis buffer was added to each well. The plates were incubated on ice for 5 min, followed by 3 rounds of Freeze/thaw cycles.
For the luciferase assays, 20 µl from the cell lysate was transferred to each well of a 96well white plate in duplicates. Forty microliters of the luciferase substrate were dispensed using the luminometer plate reader, and after 2 sec delay, three measurements were taken at 1, 5 and
For the ß-galactosidase assay, 20 µl from the cell lysate was transferred to each well of a 96-well clear plate in duplicates. Thirty microliters of 1xCCLR plus 50 µl of assay buffer were added. The plate was incubated at 37 o C for a maximum of 30 min, and the color development was monitored. At the appropriate time point, the reaction was stopped with 150 µl of Tris buffer per well. The absorbance in each well was measured at 420 nm.
Quantitative reverse transcription PCR
Total RNA was isolated using the QIAzol Lysis Reagent according to the instructions.
A. For microRNAs, one microgram of total RNA was used for reverse transcription using the miScript II RT Kit with the Hi-Flex buffer. Q-PCR was performed using miScript SYBR Green.
B. For genes, five hundred nanograms of total RNA were used for reverse transcription using the PrimeScript RT Master Mix. Q-PCR was performed using the Rotor-Gene SYBR Green.
Primer design for Q-PCR
PrimerBank was used as the source for the primers used for PCR quantitation of genes (8) .
Western blots
Western blots were performed as has been previously described (REF) . Briefly, 10-20µg of total protein extract were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis and subsequently transferred onto PVDF blotting-membrane. Subsequently, the membranes were blocked with 5% Bovine Serum Albumin Fraction V (BSA) in TBS-T (pH 7.6; 0.5% Tween 20), and incubated with the primary and secondary antibodies diluted in 5% BSA in TBS-T. Finally, the membranes were visualized using ECL and imaged with Fusion FX7. The following antibodies were used: phospho-Ser465/467 Smad2 (Cell Signaling; Cat# 3108), Smad2 (Cell Signaling; Cat# 5339), SORL1 (Abcam; Cat#ab190684), and ALK7 (Sigma; Cat# HPA007982).
Immunostaining
ALK7 (Sigma; Cat# HPA007982) and T antigen (in-house antibody) chromogenic immunostaining was performed using the automated Ventana Discovery XT as has been previously described (4) .
EdU/T antigen immunostaining: The immunofluorescence for T antigen and EdU was performed manually. After dewaxing and rehydration, sections were pretreated with heat in 10mM
Tri Na citrate buffer pH 6 using the PT module (Thermo Fisher Scientific) for 20 minutes at 95°C. After washing, the samples were incubated for 40 min with a donkey anti-rabbit AlexaFluor488 diluted 1:1000 in 1% BSA. Samples were washed, and nuclear staining was done with DAPI before mounting. Fig. 3 E and F) .
(E) Quantification of cancer cells lodged in the liver. n = 10-12. Students t-test. ns = not significant. Flow chart of the first step for the identification of potential gene targets in the case of multiple miRNAs, e.g., miR-23b cluster. The algorithm first calculates the PS score for each individual miRNA as described in the case of a single miRNA and uses the same cut-off filter of PS ≥ 0.3.
Subsequently, in a "Post-Filtering" step, to calculate the final PS of the cluster for each gene, the sum of the PS scores for each miRNA that passes the PS ≥ 0.3 bar is normalized according to the total number (n) of miRNAs in the cluster, such that the maximal PS = 1 (also see Methods). The second step of the algorithm remains the same as in the case of individual miRNAs. (A) Identification of potential miRNAs regulating Inhßb expression using Bio-miRTa.
The first column labeled as "miRNA" shows the candidate miRNA sorted according to the collective Final Score (FS) shown in the last column on the right. The columns with the headers "Target prediction algorithms" and "Experimentally validated targets" report the presence of an MRE in the Inhßb gene for the indicated miRNA. The columns with the header "Differential gene expression"
show the differential miRNA expression in normal mouse islets versus islet tumors in RT2 mice (Mouse PanNETs). There were no gain-or lost-of-function (GOF/LOF) datasets or human PanNET datasets available to be included in this analysis (NA; not-available). The intercalated columns
show the PS (based on the presence of MRE according to the first step of the algorithm), BS (based on the differential gene expression), and FS (the sum of the PS and BS scores). The miRNAs with FS>1 are shown; Supplementary Tables S5 contains the (C) ALK7 expression in MLP-like AJ-5257-1 cells treated with either control or miR23/7 anti-miRNAs. n = 6. Students t-test. ** p<0.01.
(D) ALK7 expression in control and miR-23b cluster over-expressing ßTC3 cells. 
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